Travere Therapeutics stock falls amid CEO transition news

Travere Therapeutics' shares experienced a significant drop of up to 2.3% in after-hours trading on Monday, following the company's announcement of an upcoming leadership change scheduled for December 2026. Eric Dube, Ph.D., who has served as the president and chief executive officer for nearly eight years, will relinquish his position to focus on his health and family matters.

Bradley L. Campbell, the former head of Amicus Therapeutics, will assume the role of president and CEO beginning December 1, 2026. Prior to his tenure at Amicus, Campbell held various commercial and business development positions at Genzyme and Bristol-Myers Squibb. Dube will continue as president and CEO until the transition date and will also serve as an executive advisor to the company through February 15, 2027, to ease the handover process.

Since taking the helm in January 2019, Dube has overseen regulatory approvals for Travere's therapies for IgA nephropathy and focal segmental glomerulosclerosis (FSGS), while expanding the company's pipeline and capabilities. Gary Lyons, chair of the Travere Board of Directors, emphasized that the company conducted a thorough search process to identify a candidate with the essential experience and leadership qualities needed for the next phase of growth.

The board ultimately selected Campbell for his extensive scientific, commercial, and operational expertise, as well as his proven track record in scaling rare disease therapies and advancing clinical pipelines. This news was reported with the assistance of AI technology, and later reviewed by an editor.